Status: Recruiting
A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma
The primary objective of this study is to determine the safe dose range of NRG-103 in patients and to recommend the dosage for subsequent treatment, while also evaluating the preliminary efficacy and tolerability of the product.
Participants needed: 24
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Neuregen Therapeutics Co., Ltd.Updated: Jul 17, 2026Locations: 3
Eligibility criteria
Willing to voluntarily participate in the study, able to sign the Informed Conse... [+3]
Patients with known or suspected hypersensitivity to any components of the inves... [+3]